12.63
price up icon4.73%   0.57
after-market 시간 외 거래: 12.66 0.03 +0.24%
loading
전일 마감가:
$12.06
열려 있는:
$12.29
하루 거래량:
6.74M
Relative Volume:
1.50
시가총액:
$1.31B
수익:
$45.97M
순이익/손실:
$-508.80M
주가수익비율:
-2.3047
EPS:
-5.48
순현금흐름:
$-382.65M
1주 성능:
+5.69%
1개월 성능:
+37.28%
6개월 성능:
+27.06%
1년 성능:
-49.64%
1일 변동 폭
Value
$12.29
$13.57
1주일 범위
Value
$11.30
$13.57
52주 변동 폭
Value
$5.90
$27.42

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
명칭
Intellia Therapeutics Inc
Name
전화
857-285-6200
Name
주소
40 ERIE STREET, CAMBRIDGE, MA
Name
직원
598
Name
트위터
@intelliatweets
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
NTLA's Discussions on Twitter

NTLA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NTLA
Intellia Therapeutics Inc
12.63 1.24B 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-21 업그레이드 Wolfe Research Peer Perform → Outperform
2025-03-05 개시 H.C. Wainwright Buy
2025-02-28 다운그레이드 Goldman Neutral → Sell
2025-02-28 다운그레이드 JP Morgan Overweight → Neutral
2025-01-27 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-02-23 다운그레이드 Goldman Buy → Neutral
2024-02-15 개시 Wolfe Research Peer Perform
2023-04-13 개시 Canaccord Genuity Buy
2023-03-21 개시 Bernstein Outperform
2023-03-14 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-02-01 개시 Cantor Fitzgerald Overweight
2023-01-24 업그레이드 Citigroup Sell → Neutral
2023-01-19 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 개시 Morgan Stanley Overweight
2022-09-21 개시 JP Morgan Overweight
2022-09-01 개시 Citigroup Sell
2022-06-17 개시 BMO Capital Markets Market Perform
2022-06-16 개시 BofA Securities Buy
2022-04-28 개시 Credit Suisse Outperform
2022-02-18 개시 William Blair Outperform
2022-02-07 업그레이드 Oppenheimer Perform → Outperform
2022-01-31 개시 Cowen Outperform
2022-01-07 개시 Piper Sandler Overweight
2021-10-05 개시 Guggenheim Buy
2021-09-24 개시 Stifel Buy
2021-06-28 재확인 H.C. Wainwright Buy
2021-06-11 개시 H.C. Wainwright Buy
2021-05-07 업그레이드 ROTH Capital Neutral → Buy
2021-05-04 개시 RBC Capital Mkts Outperform
2021-03-04 개시 JMP Securities Mkt Outperform
2020-12-22 다운그레이드 Robert W. Baird Outperform → Neutral
2020-10-27 개시 Truist Buy
2020-10-14 개시 Wells Fargo Overweight
2020-09-18 개시 Goldman Buy
2020-02-28 업그레이드 Oppenheimer Perform → Outperform
2020-02-14 다운그레이드 Wedbush Outperform → Neutral
2019-11-01 업그레이드 Raymond James Mkt Perform → Outperform
2019-07-09 개시 Robert W. Baird Outperform
2019-06-10 개시 ROTH Capital Neutral
2019-05-03 업그레이드 Wedbush Neutral → Outperform
2019-04-12 개시 Evercore ISI Outperform
2018-11-02 다운그레이드 Wedbush Outperform → Neutral
2018-10-29 개시 Credit Suisse Neutral
2018-09-21 개시 Raymond James Mkt Perform
2018-05-15 업그레이드 Chardan Capital Markets Neutral → Buy
2018-03-08 개시 JMP Securities Mkt Outperform
2017-11-01 재확인 Jefferies Buy
2017-06-22 재개 Jefferies Buy
2017-03-28 개시 Chardan Capital Markets Buy
2016-08-05 업그레이드 Jefferies Hold → Buy
모두보기

Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스

pulisher
11:36 AM

Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options - Nasdaq

11:36 AM
pulisher
Jul 20, 2025

What drives Intellia Therapeutics Inc. stock priceExplosive wealth accumulation - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

Is Intellia Therapeutics Inc. a good long term investmentUnmatched profit growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Intellia Therapeutics Inc. Stock Analysis and ForecastFree Risk Assessment Services - Autocar Professional

Jul 19, 2025
pulisher
Jul 19, 2025

What analysts say about Intellia Therapeutics Inc. stockOverwhelming financial success - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Intellia Therapeutics: A High-Volatility, High-Reward Play in the CRISPR Revolution - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At ‘Buy’ (NTLA) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 17, 2025

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks

Jul 17, 2025
pulisher
Jul 16, 2025

Intellia Faces The Biotech Balancing Act As Shares Slide - Finimize

Jul 16, 2025
pulisher
Jul 16, 2025

ATTR Amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks

Jul 15, 2025
pulisher
Jul 09, 2025

Intellia Therapeutics (NTLA) Soars 9.08% on Phase III Trial - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Possible Bearish Signals With Intellia Therapeutics Insiders Disposing Stock - simplywall.st

Jul 09, 2025
pulisher
Jul 08, 2025

Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

Gene Editing Leader Intellia Expands Team with 23,800 Share RSU Grant Package - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

Intellia Gains 29.8% in a Month: How Should You Play the Stock? - Nasdaq

Jul 07, 2025
pulisher
Jul 03, 2025

Insider Sell: Eliana Clark Sells Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus

Jul 03, 2025
pulisher
Jul 03, 2025

Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data - Insider Monkey

Jul 03, 2025
pulisher
Jul 02, 2025

Insider Sell Alert: Jesse Goodman Sells Shares of Intellia Thera - GuruFocus

Jul 02, 2025
pulisher
Jul 02, 2025

The Best Biotech Stocks to Buy - Morningstar

Jul 02, 2025
pulisher
Jun 28, 2025

Intellia Therapeutics gets FDA RMAT status for its heart disorder treatment - MSN

Jun 28, 2025
pulisher
Jun 25, 2025

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Yahoo Finance

Jun 25, 2025
pulisher
Jun 23, 2025

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress - Insider Monkey

Jun 23, 2025
pulisher
Jun 22, 2025

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress. - Yahoo Finance

Jun 22, 2025
pulisher
Jun 21, 2025

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely? - Yahoo Finance

Jun 21, 2025
pulisher
Jun 18, 2025

Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News

Jun 18, 2025
pulisher
Jun 17, 2025

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive

Jun 17, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics (NTLA) Receives Reiterated Buy Rating with Stable Price Target | NTLA Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics Announces Positive Phase 1 Trial Data - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks - MarketScreener

Jun 16, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Ph - GuruFocus

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Revolutionary Gene Therapy Eliminates HAE Attacks for 2 Years: Breakthrough Phase 1 Trial Results - Stock Titan

Jun 15, 2025
pulisher
Jun 14, 2025

Intellia Therapeutics’ SWOT analysis: gene editing stock faces pivotal year - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

Intellia Therapeutics Holds Annual Stockholders’ Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 10, 2025

California State Teachers Retirement System Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World

Jun 10, 2025
pulisher
Jun 06, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - mx.advfn.com

Jun 05, 2025
pulisher
Jun 04, 2025

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView

Jun 04, 2025
pulisher
Jun 04, 2025

Intellia Therapeutics (NASDAQ:NTLA) Given New $54.00 Price Target at Canaccord Genuity Group - Defense World

Jun 04, 2025

Intellia Therapeutics Inc (NTLA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):